Related Experiment Video

Updated: Jun 21, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.6K

Delta-like ligand 3: A promising target against small cell lung cancer

Xin Nie1, Yu-Meng Tian1, Yue Yuan1

  • 1Department of Medical Oncology Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences Beijing China.

Aging Medicine (Milton (N.S.W))
|July 8, 2024
PubMed

Insights

New DLL3-targeting agents show promise for treating refractory small cell lung cancer. This commentary reviews current knowledge on these novel therapies for patients with limited options.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Small cell lung cancer (SCLC) remains a challenging diagnosis with limited effective treatments for refractory disease.
  • Delta-like protein 3 (DLL3) is a promising therapeutic target in SCLC due to its overexpression on tumor cells.

Purpose of the Study:

  • To provide an overview of the current knowledge regarding novel DLL3-targeting agents.
  • To discuss the therapeutic potential of these agents in refractory SCLC.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of data on DLL3-targeting therapies.

Main Results:

  • Several novel DLL3-targeting agents, including antibody-drug conjugates and bispecific antibodies, are under investigation.
  • Early clinical data suggest potential efficacy and manageable safety profiles for some agents.

Conclusions:

  • DLL3-targeting agents represent a significant advancement in the treatment landscape for refractory SCLC.
  • Further clinical development is warranted to establish the role of these novel therapies.

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K